AREDS supplement found cost-effective in wet AMD

A study based on a patient level simulation model demonstrated that the use of Age-Related Eye Disease Study supplements in patients with AREDS category 4 neovascular age-related macular degeneration in one eye would be highly cost effective in the U.K. National Health Service setting, leading to significant saving from decreased need of ranibizumab injections. [...]this model demonstrates that the use of AREDS supplements is a dominant cost-effective intervention for use for AREDS category 4 patients with neovascular AMD in one eye in the U.K.," the authors noted, while publicly funding AREDS supplements for category 3 "would depend on the health care system willingness to pay" - by Michela Cimberle рсои Disclosure: Lee reports no financial disclosures.